The gene editing market is on an upward trajectory, poised to double in value from USD 5.3 billion in 2023 to a staggering USD 10.6 billion by 2028, sporting a remarkable CAGR of 15.0%. Gene editing, also known as genome engineering, has rapidly evolved to become a powerful tool for the targeted alteration of DNA sequences in organisms and cells. In this article, we explore the dynamics and key players driving the growth of the gene editing market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
Unlocking the Potential: Gene Editing Defined
Gene editing, often referred to as genome engineering, involves the precise insertion, deletion, or replacement of DNA at specific locations within an organism’s or cell’s genome. This revolutionary process is predominantly carried out in laboratories using cutting-edge genome-editing tools, such as CRISPR, TALEN, and ZFN. These tools allow scientists to efficiently and accurately modify cell lines and the genomes of animals and plants.
The Global Gene Editing Market: A Landscape of Innovation
The global gene editing market is a dynamic arena with numerous players contributing to its rapid expansion. Prominent companies, including Merck KGaA, Thermo Fisher Scientific, Inc., GenScript, Agilent Technologies, PerkinElmer, Lonza, Tecan Life Sciences, Sangamo Therapeutics, and many more, are at the forefront of this revolutionary field.
Leading the Way: Industry Pioneers
Three key players are significantly influencing the gene editing market:
- Thermo Fisher Scientific (US): Thermo Fisher Scientific offers an extensive and integrated suite of solutions and services for clinical science, laboratory research, and analysis. Their portfolio encompasses gene modification and precision genome editing. The company provides high-efficiency delivery systems, contributing to the development of gene expression systems, modified genes, and stable engineered cell lines. Notably, their genome editing technologies, including CRISPR-Cas9 and TAL effectors, are widely accessible through licensing for various applications, further bolstering their presence in the gene editing market.
- Merck KGaA (Germany): Merck KGaA, a global heavyweight, collaborates closely with pharmaceutical and biotechnology firms engaged in genomics and personalized medicine. The company’s proprietary gene editing technology is licensed to these companies, strengthening its market position. In a significant move in March 2022, Merck signed a collaboration and license agreement with BetterSeeds, an Israeli company focusing on plant breeding through CRISPR. This agreement, facilitated by Merck’s Life Science division, aims to expand the reach of their proprietary technology, with Merck holding a substantial number of CRISPR-related patents globally.
- GenScript (China): GenScript is a major player in the gene editing market, offering a comprehensive range of products and services in the gene editing domain. The company provides validated CRISPR products, services, and resources through its partnership with Feng Zhang’s laboratory at the Broad Institute of MIT and Harvard. GenScript’s expertise in CRISPR technology is the result of significant research and development investments. They offer versatile solutions applicable to cell therapy, CAR-T cell therapy, and gene therapy applications, making them a formidable competitor in the gene editing market.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
Conclusion: A Future Fueled by Innovation
The gene editing market is experiencing unprecedented growth, driven by the innovation and contributions of industry leaders. As gene editing technologies become increasingly accessible and versatile, their applications are set to revolutionize the fields of medicine, agriculture, and biotechnology. This transformative market holds the promise of a future where genetic modification and precision genome editing play pivotal roles in shaping our world. As the industry continues to evolve, it remains a space to watch for groundbreaking advancements and exciting possibilities.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441